title: A molecular dynamics study of the BACE1 conformational change from Apo to closed form induced by hydroxyethylamine derived compounds.
abstract: BACE1 is an aspartyl protease which is a therapeutic target for Alzheimer's disease (AD) because of its participation in the rate-limiting step in the production of Aβ-peptide, the accumulation of which produces senile plaques and, in turn, the neurodegenerative effects associated with AD. The active site of this protease is composed in part by two aspartic residues (Asp93 and Asp289). Additionally, the catalytic site has been found to be covered by an antiparallel hairpin loop called the flap. The dynamics of this flap are fundamental to the catalytic function of the enzyme. When BACE1 is inactive (Apo), the flap adopts an open conformation, allowing a substrate or inhibitor to access the active site. Subsequent interaction with the ligand induces flap closure and the stabilization of the macromolecular complex. Further, the protonation state of the aspartic dyad is affected by the chemical nature of the species entering the active site, so that appropriate selection of protonation states for the ligand and the catalytic residues will permit the elucidation of the inhibitory pathway for BACE1. In the present study, comparative analysis of different combinations of protonation states for the BACE1-hydroxyethylamine (HEA) system is reported. HEAs are potent inhibitors of BACE1 with favorable pharmacological and kinetic properties, as well as oral bioavailability. The results of Molecular Dynamics (MD) simulations and population density calculations using 8 different parameters demonstrate that the LnAsp289 configuration (HEA with a neutral amine and the Asp289 residue protonated) is the only one which permits the expected conformational change in BACE1, from apo to closed form, after flap closure. Additionally, differences in their capacities to establish and maintain interactions with residues such as Asp93, Gly95, Thr133, Asp289, Gly291, and Asn294 during this step allow differentiation among the inhibitory activities of the HEAs. The results and methodology here reported will serve to elucidate the inhibitory pathway of other families of compounds that act as BACE1 inhibitors, as well as the design of better leader compounds for the treatment of AD.
authors.affiliation: Grupo de Química Bioorgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Cartagena, Colombia.
authors.forename: Carlos
authors.initials: C
authors.lastname: Gueto-Tettay
authors.affiliation: Grupo de Química Bioorgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Cartagena, Colombia.
authors.forename: Joshua
authors.initials: J
authors.lastname: Zuchniarz
authors.affiliation: Grupo de Química Bioorgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Cartagena, Colombia.
authors.forename: Yeyson
authors.initials: Y
authors.lastname: Fortich-Seca
authors.affiliation: Grupo de Química Bioorgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Cartagena, Colombia.
authors.forename: Luis Roberto
authors.initials: LR
authors.lastname: Gueto-Tettay
authors.affiliation: Grupo de Química Bioorgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Cartagena, Colombia. Electronic address: jdrososr@unicartagena.edu.co.
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Drosos-Ramirez
mesh_terms: D053829:Amyloid Precursor Protein Secretases / Q000737:chemistry*; D001059:Apoproteins / Q000737:chemistry; D018360:Crystallography, X-Ray; D004983:Ethanolamines / Q000737:chemistry; D005021:Ethylamines / Q000737:chemistry*; D008024:Ligands; D056004:Molecular Dynamics Simulation; D011487:Protein Conformation; D011522:Protons
chemical_list: D001059:Apoproteins; D004983:Ethanolamines; D005021:Ethylamines; D008024:Ligands; D011522:Protons; D053829:Amyloid Precursor Protein Secretases; C041564:ethylamine
keywords: Alzheimer’s disease; BACE1; Flap; GROMACS; Hydroxyethylamines; Population density